FDA Approves Tarsus’s Lotilaner (XDEMVY™ ophthalmic solution) for the treatment of Demodex blepharitis a common eyelid disease Read More..

Tarsus Pharmaceuticals Inc., in a statement announced FDA approval of Lotilaner ophthalmology solution 0.25% (XDEMVY™). XDEMVY is an ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis. The Lotilaner ophthalmic solution is the first FDA approved treatment for Demodex blepharitis. The medicine targets Demodex mites, the root cause of Demodex blepharitis.  Demodex blepharitis  is a common eyelid disease that is caused by an infestation of Demodex mites, the most common ectoparasite found on human skin. It is caused by overpopulation of Demodex mites in the eyelash follicles